-
公开(公告)号：US09670259B2
公开(公告)日：2017-06-06
申请号：US14775936
申请日：2014-03-14
CPC分类号： C07K14/4722 , A61K38/10 , A61K38/16 , A61K38/1709 , A61K39/3955 , A61K47/66 , C07K16/28
摘要： The present invention is directed to methods and compositions comprising G-protein-coupled receptor kinase interacting protein-1 (GIT1) inhibitors that are suitable for inhibiting angiogenesis in a subject and treating related conditions.
-
2.发明申请MODULATION OF ANGIOGENESIS AND RELATED CONDITIONS USING INHIBITORS OF G-PROTEIN-COUPLED RECEPTOR KINASE INTERACTING PROTEIN-1 (GIT1) 有权使用G蛋白偶联受体激酶相互作用蛋白-1（GIT1）的抑制剂调节血管发生和相关条件公开(公告)号：US20160024163A1
公开(公告)日：2016-01-28
申请号：US14775936
申请日：2014-03-14
IPC分类号： C07K14/47 , A61K38/17 , A61K39/395 , C07K16/28 , A61K47/48
CPC分类号： C07K14/4722 , A61K38/10 , A61K38/16 , A61K38/1709 , A61K39/3955 , A61K47/66 , C07K16/28
摘要： The present invention is directed to methods and compositions comprising G-protein-coupled receptor kinase interacting protein-1 (GIT1) inhibitors that are suitable for inhibiting angiogenesis in a subject and treating related conditions.
摘要翻译： 本发明涉及包含G蛋白偶联受体激酶相互作用蛋白-1（GIT1）抑制剂的方法和组合物，其适于抑制受试者的血管发生并治疗相关病症。
-
3.发明授权Thioredoxin interacting protein (TXNIP) as regulator of vascular function 有权硫氧还蛋白相互作用蛋白（TXNIP）作为血管功能的调节剂公开(公告)号：US08999944B2
公开(公告)日：2015-04-07
申请号：US11814442
申请日：2006-01-20
申请人： Bradford C. Berk
发明人： Bradford C. Berk
CPC分类号： G01N33/6893 , G01N2500/02 , G01N2500/10 , G01N2800/32
摘要： The present invention relates to screening assays for the identification of agents that can modify the interaction of thioredoxin interacting protein (TXNEP) on thioredoxin (TRX)5 preferably by inhibiting TXNIP downregulation of TXR. The use of such compounds, including the disclosed siRNA and antibodies against TXNIP, is contemplated for therapeutic or prophylactic treatment of vascular disease conditions, particularly those associated with pro-inflammatory activity of the TNF-ASK1-JNK-p38 pathways.
摘要翻译： 本发明涉及用于鉴定可以修饰硫氧还蛋白相互作用蛋白（TXNEP）对硫氧还蛋白（TRX）5的相互作用的试剂的筛选测定，优选通过抑制TXR的TXNIP下调。 预期使用包括所公开的siRNA和针对TXNIP的抗体的这些化合物用于治疗或预防性治疗血管疾病状况，特别是与TNF-ASK1-JNK-p38途径的促炎活性相关的那些。
-
4.发明申请Thioredoxin Interacting Protein (TXNIP) As Regulator Of Vascular Function 有权硫氧还蛋白相互作用蛋白（TXNIP）作为血管功能调节剂公开(公告)号：US20110097317A1
公开(公告)日：2011-04-28
申请号：US11814442
申请日：2006-01-20
申请人： Bradford C. Berk
发明人： Bradford C. Berk
IPC分类号： A61K39/395 , G01N33/566 , C12Q1/02 , G01N33/53 , C12Q1/68 , A61K38/02
CPC分类号： G01N33/6893 , G01N2500/02 , G01N2500/10 , G01N2800/32
摘要： The present invention relates to screening assays for the identification of agents that can modify the interaction of thioredoxin interacting protein (TXNEP) on thioredoxin (TRX)5 preferably by inhibiting TXNIP downregulation of TXR. The use of such compounds, including the disclosed siRNA and antibodies against TXNIP, is contemplated for therapeutic or prophylactic treatment of vascular disease conditions, particularly those associated with pro-inflammatory activity of the TNF- ASK1-JNK-p38 pathways.
摘要翻译： 本发明涉及用于鉴定可以修饰硫氧还蛋白相互作用蛋白（TXNEP）对硫氧还蛋白（TRX）5的相互作用的试剂的筛选测定，优选通过抑制TXR的TXNIP下调。 预期使用这些化合物，包括所公开的siRNA和针对TXNIP的抗体，用于治疗或预防性治疗血管疾病病症，特别是与TNF-ASK1-JNK-p38途径的促炎活性相关的那些。
-
-
-
搜索结果
4 条记录 (耗时 0.018 秒)
